Mohammadi A, Karimian A, Shokri K, Mohammadi A, Hazhir-Karzar N, Bahar R
J Cardiovasc Transl Res. 2025; .
PMID: 40080261
DOI: 10.1007/s12265-025-10603-4.
Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B
Signal Transduct Target Ther. 2025; 10(1):73.
PMID: 40059188
PMC: 11891339.
DOI: 10.1038/s41392-024-02112-8.
Bettinsoli V, Melzi G, Marchese I, Pantaleoni S, Passoni F, Corsini E
Curr Res Toxicol. 2025; 8:100222.
PMID: 40027547
PMC: 11872130.
DOI: 10.1016/j.crtox.2025.100222.
Leckie J, Yokota T
Genes (Basel). 2025; 16(2).
PMID: 40004514
PMC: 11855077.
DOI: 10.3390/genes16020185.
Sartorelli J, Ng J, Rahim A, Waddington S, Kurian M
J Neurol. 2025; 272(3):220.
PMID: 39985571
PMC: 11846774.
DOI: 10.1007/s00415-025-12940-5.
efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney.
Tsuboi T, Hattori K, Ishimoto T, Imai K, Doke T, Hagita J
Mol Ther Nucleic Acids. 2025; 36(1):102387.
PMID: 39850319
PMC: 11754010.
DOI: 10.1016/j.omtn.2024.102387.
Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy.
Tzaban S, Stern O, Zisman E, Eisenberg G, Klein S, Frankenburg S
Front Immunol. 2025; 15():1490035.
PMID: 39845971
PMC: 11752881.
DOI: 10.3389/fimmu.2024.1490035.
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington's disease.
Ou K, Jia Q, Li D, Li S, Li X, Yin P
Transl Neurodegener. 2025; 14(1):4.
PMID: 39838446
PMC: 11748355.
DOI: 10.1186/s40035-025-00466-9.
Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy.
Senol H, Yildiz G, Polat A, Aydin A, Hiz A, Soylu A
Brain Behav. 2025; 15(1):e70221.
PMID: 39829133
PMC: 11743982.
DOI: 10.1002/brb3.70221.
The emerging role of long non-coding RNA SOX2-OT in cancers and non-malignant diseases.
Yang J, Tan F, Chen Y, Li X, Yuan C
J Physiol Biochem. 2024; .
PMID: 39702742
DOI: 10.1007/s13105-024-01059-2.
Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges.
Ruchi R, Raman G, Kumar V, Bahal R
Expert Opin Drug Discov. 2024; 20(1):63-80.
PMID: 39653607
PMC: 11823135.
DOI: 10.1080/17460441.2024.2440095.
Detecting the Major Degradation Products of Phosphorothioate Oligonucleotides by Chemical Derivatization and Weak Anion Exchange Chromatography.
Roussis S, Gabriel C, Rodriguez A, Rentel C
ACS Omega. 2024; 9(48):47822-47830.
PMID: 39651088
PMC: 11618427.
DOI: 10.1021/acsomega.4c08543.
Exploring non-coding variants and evaluation of antisense oligonucleotides for splicing redirection in Usher syndrome.
Garcia-Bohorquez B, Barberan-Martinez P, Aller E, Jaijo T, Minguez P, Rodilla C
Mol Ther Nucleic Acids. 2024; 35(4):102374.
PMID: 39629117
PMC: 11612772.
DOI: 10.1016/j.omtn.2024.102374.
Nucleic acid drugs: recent progress and future perspectives.
Sun X, Setrerrahmane S, Li C, Hu J, Xu H
Signal Transduct Target Ther. 2024; 9(1):316.
PMID: 39609384
PMC: 11604671.
DOI: 10.1038/s41392-024-02035-4.
Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma.
Khuu A, Verreault M, Colin P, Tran H, Idbaih A
Cells. 2024; 13(22).
PMID: 39594617
PMC: 11592788.
DOI: 10.3390/cells13221869.
Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca and Mg in the formulation.
Miller R, Paquette J, Barker A, Sapp E, McHugh N, Bramato B
Mol Ther Nucleic Acids. 2024; 35(4):102359.
PMID: 39554992
PMC: 11567125.
DOI: 10.1016/j.omtn.2024.102359.
A Manual for Genome and Transcriptome Engineering.
Doctor Y, Sanghvi M, Mali P
IEEE Rev Biomed Eng. 2024; 18:250-267.
PMID: 39514364
PMC: 11875898.
DOI: 10.1109/RBME.2024.3494715.
Technologies for Targeted RNA Degradation and Induced RNA Decay.
Mikutis S, Bernardes G
Chem Rev. 2024; 124(23):13301-13330.
PMID: 39499674
PMC: 11638902.
DOI: 10.1021/acs.chemrev.4c00472.
LncRNAs in melanoma phenotypic plasticity: emerging targets for promising therapies.
Beatriz Cristina Biz T, Carolina de Sousa C, Frank John S, Miriam Galvonas J
RNA Biol. 2024; 21(1):81-93.
PMID: 39498940
PMC: 11540095.
DOI: 10.1080/15476286.2024.2421672.
Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials.
Ogieuhi I, Callender K, Odukudu G, Obi E, Muzofa K, Babalola A
High Blood Press Cardiovasc Prev. 2024; 32(1):33-47.
PMID: 39476283
DOI: 10.1007/s40292-024-00682-w.